Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

BACKGROUND Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-kappaB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density. Given its unique actions, denosumab may be useful in the treatment of osteoporosis. METHODS We enrolled 7868 women between the ages of 60 and 90 years who had a bone mineral density T score of less than -2.5 but not less than -4.0 at the lumbar spine or total hip. Subjects were randomly assigned to receive either 60 mg of denosumab or placebo subcutaneously every 6 months for 36 months. The primary end point was new vertebral fracture. Secondary end points included nonvertebral and hip fractures. RESULTS As compared with placebo, denosumab reduced the risk of new radiographic vertebral fracture, with a cumulative incidence of 2.3% in the denosumab group, versus 7.2% in the placebo group (risk ratio, 0.32; 95% confidence interval [CI], 0.26 to 0.41; P<0.001)--a relative decrease of 68%. Denosumab reduced the risk of hip fracture, with a cumulative incidence of 0.7% in the denosumab group, versus 1.2% in the placebo group (hazard ratio, 0.60; 95% CI, 0.37 to 0.97; P=0.04)--a relative decrease of 40%. Denosumab also reduced the risk of nonvertebral fracture, with a cumulative incidence of 6.5% in the denosumab group, versus 8.0% in the placebo group (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01)--a relative decrease of 20%. There was no increase in the risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcemia, and there were no cases of osteonecrosis of the jaw and no adverse reactions to the injection of denosumab. CONCLUSIONS Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis. (ClinicalTrials.gov number, NCT00089791.)

[1]  M. Whyte.  The long and the short of bone therapy. , 2006, The New England journal of medicine.

[2]  T. Martin,et al.  Paracrine regulation of osteoclast formation and activity: milestones in discovery. , 2004, Journal of musculoskeletal & neuronal interactions.

[3]  P. Miller,et al.  Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  N. Watts,et al.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy , 2008, Osteoporosis International.

[5]  Martin Tj.  Paracrine regulation of osteoclast formation and activity: milestones in discovery. , 2004 .

[6]  O. Johnell,et al.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures , 2006, Osteoporosis International.

[7]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[8]  M. Bouxsein,et al.  Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[10]  P. Delmas.  Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. , 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[11]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[12]  S. Cummings,et al.  Recommendations for the Clinical Evaluation of Agents for Treatment of Osteoporosis: Consensus of an Expert Panel Representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF) , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  C. Christiansen,et al.  Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  R. Kagan,et al.  Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis , 2004, Current medical research and opinion.

[15]  J. S. San Martin,et al.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.

[16]  Jacques P. Brown,et al.  Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  P. Miller,et al.  Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .

[18]  M. Nevitt,et al.  Vertebral fracture assessment using a semiquantitative technique , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  Gail A. Greendale,et al.  Outcomes of Osteoporotic Fractures , 2001 .

[20]  S. Boonen,et al.  Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Postmenopausal Osteoporosis , 2004, Calcified Tissue International.

[21]  R. Goodman,et al.  The effect of risedronate on the risk of hip fracture in elderly women. , 2001, The New England journal of medicine.

[22]  H. Genant,et al.  Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. , 1993, The American journal of medicine.

[23]  R. Vines.  THE LONG AND THE SHORT , 1977, The Medical journal of Australia.

[24]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[25]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[26]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[27]  V. French,et al.  The long and the short of it , 1993, Nature.

[28]  S. Cummings,et al.  BMD at Multiple Sites and Risk of Fracture of Multiple Types: Long‐Term Results From the Study of Osteoporotic Fractures , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  P. Tugwell,et al.  Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2024, The Cochrane database of systematic reviews.

[30]  A. Capron,et al.  Osteoporosis Panel Summary , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  Chantal Couture,et al.  Mechanisms of action , 1994, Schizophrenia Research.

[32]  J. S. San Martin,et al.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. , 2008, The Journal of clinical endocrinology and metabolism.

[33]  S. Silverman,et al.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. , 2006, Mayo Clinic proceedings.

[34]  J. Adachi,et al.  Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. , 2002, Archives of internal medicine.

[35]  G. Guyatt,et al.  Ethical Issues in Stopping Randomized Trials Early Because of Apparent Benefit , 2007, Annals of Internal Medicine.

[36]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[37]  Alan Agresti,et al.  Categorical Data Analysis , 2003 .

[38]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[39]  P. Tugwell,et al.  Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2008, The Cochrane database of systematic reviews.

[40]  S. Cummings,et al.  Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.

[41]  S. Silverman,et al.  Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.